Abstract
Progressive telomere shortening is thought to be important in the regulation of cellular senescence and that the upregulation or reactivation of telomerase activity may be a critical if not rate limiting step in the development of neoplastic cells. To obtain information about telomeres and telomerase activity in hematopoietic neoplasia at various disease stages, we evaluated 54 samples obtained from 41 patients with chronic myeloid leukemia (CML) using a combination of fluorescent-telomeric repeat amplification protocol and an internal telomerase assay standard. The terminal restriction fragment (TRF) lengths in the blast phase was reduced compared to that in the chronic phase (4.53 ± 0.72 kb vs 6.13 ± 1.68 kb; P = 0.0005). All samples obtained from CML in the chronic phase (n = 33) had detectable telomerase activity above background, regardless of age. In the blast phase (n = 21), a significant increase of telomerase activity was detected compared to that in the chronic phase (33.84 ± 37.86% vs 6.08 ± 3.21; P = 0.016). Among patients in the blastic phase, 50% of patients had moderate to high telomerase activity (>10 relative value), and the remaining patients had telomerase activity higher than that in the normal peripheral blood cells. No significant differences in hematologic findings, duration of chronic phase or blast phase, and telomere length in the blastic phase were noted between these two groups separated by telomerase activity. CML patients with moderate to high telomerase activity had a high frequency of additional cytogenetic changes (P = 0.01).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohyashiki, K., Ohyashiki, J., Iwama, H. et al. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 11, 190–194 (1997). https://doi.org/10.1038/sj.leu.2400560
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400560
Keywords
This article is cited by
-
The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia
Journal of Cancer Research and Clinical Oncology (2023)
-
Expression pattern of hTERT telomerase subunit gene in different stages of chronic myeloid leukemia
Molecular Biology Reports (2014)
-
Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia
Journal of Hematology & Oncology (2013)
-
A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1
Leukemia (2013)
-
Knockdown of hTERT Alters Biophysical Properties of K562 Cells Resulting in Decreased Migration Rate In Vitro
Cell Biochemistry and Biophysics (2011)